Citi lowered its price target on Bellicum Pharmaceuticals (NASDAQ: BLCM) to $25.00 (from $27.00) while maintaining a Buy rating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Bellicum Pharma (BLCM) Tops Q4 EPS by 8cMarch 13, 2018 4:04 PM Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017March 13, 2018 4:01 PM Bellicum Pharma (BLCM) Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501March 13, 2018 7:05 AM Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501March 13, 2018 7:00 AM